| Price | 1,289.60on 30-10-2020 at 16:30:00 |
|---|---|
| Change | -14.60 -1.12% |
| Buy | 1,289.80 |
| Sell | 1,289.40 |
| Buy / Sell GSK Shares | |
| Last Trade: | Buy 5 at 1,286.80p |
| Day's Volume: | 4,147,494 |
| Last Close: | 1,304.20p |
| Open: | 1,295.20p |
| ISIN: | GB0009252882 |
| Day's Range | 1,284.00p - 1,305.20p |
| 52wk Range: | 1,284.00p - 1,857.00p |
| Market Capitalisation: | £64,704m |
| VWAP: | 0.00p |
| Shares in Issue: | 5,017m |
Sector: Medicine and Biotech Research
Listed in: FTSE 100, FTSE All-Share, FTSE 350, FTSE 350 High Yield
Recent Trades History Glaxosmithkline (GSK) |
||||
| Buy/Sell | Volume | Trade Prc | Trade Type | Trade Time |
|---|---|---|---|---|
| Buy* | 5 | 1,286.80 | Ordinary | 15:09:46 - 30-Oct-20 |
| Buy* | 99 | 1,286.76 | Ordinary | 15:09:45 - 30-Oct-20 |
| Buy* | 5 | 1,286.60 | Ordinary | 15:09:46 - 30-Oct-20 |
| Sell* | 120 | 1,286.60 | Automatic Execution | 15:09:45 - 30-Oct-20 |
| Sell* | 605 | 1,286.60 | Automatic Execution | 15:09:45 - 30-Oct-20 |
| Sell* | 185 | 1,286.60 | Automatic Execution | 15:09:45 - 30-Oct-20 |
| Buy* | 694 | 1,287.96 | Ordinary | 15:08:39 - 30-Oct-20 |
| Sell* | 80 | 1,287.80 | Automatic Execution | 15:08:40 - 30-Oct-20 |
| Sell* | 412 | 1,287.80 | Automatic Execution | 15:08:40 - 30-Oct-20 |
| Sell* | 989 | 1,287.80 | Automatic Execution | 15:08:40 - 30-Oct-20 |
Share Price History for Glaxosmithkline |
|||||
| Date | Open | High | Low | Close | |
|---|---|---|---|---|---|
| 29th Oct 2020 (Thu) | 1,307.40 | 1,341.00 | 1,293.20 | 1,318.30 | |
| 28th Oct 2020 (Wed) | 1,344.60 | 1,368.20 | 1,302.60 | 1,318.30 | |
| 27th Oct 2020 (Tue) | 1,339.60 | 1,363.80 | 1,335.00 | 1,361.00 | |
| 26th Oct 2020 (Mon) | 1,339.80 | 1,358.20 | 1,334.80 | 1,346.90 | |
| 23rd Oct 2020 (Fri) | 1,333.20 | 1,354.60 | 1,330.20 | 1,341.30 | |
| 22nd Oct 2020 (Thu) | 1,344.80 | 1,346.00 | 1,324.40 | 1,337.20 | |
| 21st Oct 2020 (Wed) | 1,387.80 | 1,388.40 | 1,352.20 | 1,355.10 | |
| 20th Oct 2020 (Tue) | 1,403.80 | 1,407.40 | 1,380.20 | 1,387.60 | |
| 19th Oct 2020 (Mon) | 1,411.40 | 1,421.20 | 1,396.60 | 1,398.30 | |
| 16th Oct 2020 (Fri) | 1,390.00 | 1,417.20 | 1,387.60 | 1,411.40 | |
| 15th Oct 2020 (Thu) | 1,414.20 | 1,416.60 | 1,376.20 | 1,379.70 | |
| 14th Oct 2020 (Wed) | 1,452.60 | 1,461.60 | 1,425.60 | 1,428.50 | |
| 13th Oct 2020 (Tue) | 1,437.20 | 1,448.20 | 1,430.00 | 1,436.30 | |
| 12th Oct 2020 (Mon) | 1,438.80 | 1,447.60 | 1,431.40 | 1,431.40 | |
| 9th Oct 2020 (Fri) | 1,426.00 | 1,444.20 | 1,426.00 | 1,430.20 | |
| 8th Oct 2020 (Thu) | 1,414.00 | 1,436.00 | 1,412.00 | 1,430.20 | |
| 7th Oct 2020 (Wed) | 1,430.80 | 1,437.80 | 1,411.80 | 1,416.80 | |
| 6th Oct 2020 (Tue) | 1,448.60 | 1,448.80 | 1,423.00 | 1,430.00 | |
| 5th Oct 2020 (Mon) | 1,445.80 | 1,455.20 | 1,438.80 | 1,450.40 | |
| 2nd Oct 2020 (Fri) | 1,433.60 | 1,445.00 | 1,428.40 | 1,439.70 | |
| 1st Oct 2020 (Thu) | 1,468.60 | 1,474.80 | 1,443.70 | 1,444.00 | |
| 30th Sep 2020 (Wed) | 1,446.80 | 1,477.20 | 1,443.00 | 1,455.20 | |
GlaxoSmithKline, or 'GSK', is one of the world's leading pharmaceutical companies researching medicines and vacines alike for the World Health Organization's three priority diseases: HIV/AIDS, Malaria and Tuberculosis. With an estimated 7% of the world's pharmaceutical market under its wing, GSK remains one of the industry leaders globally but remains committed to the research and application of life changing and marketable drugs.
If investing in science seems a little confusing and unpredictable then perhaps some of GSK's over-the-counter and more recognisable products will help to convince; these include Gaviscon and Panadol, smoking control products such as Nicorette/Niquitin and nutritional healthcare drinks such as Lucozade, Ribena and Horlicks.
On 23rd January 2009, GSK announced that it had signed an agreement with UCB S.A to acquire its marketed product portfolio in certain parts of the Middle East, Africa, Latin America and Asia Pacific, for a cash consideration of some £484 million. President of Emerging Markets at GSK, Abbas Hussain, said that "This acquisition will strengthen and expand GSK's product portfolio in these countries, helping us to meet the needs of patients, particularly in the areas of epilepsy and respiratory." Under the agreement, GSK acquires several leading pharmaceutical brands and investors will be interested to know that the commercial operations and product distribution rights included represent approximately 3-4% of UCB's 2008 expected revenue of at least £3.09 billion. At the time of Mr Hussain speaking, share prices for GSK were steady at 1,226.00p with a "strong buy" recommendation from brokers.
News - Thursday, October 29, 2020
Jesse Goodman, Director, bought 752 shares in the company on the 28th October 20......
News - Thursday, October 29, 2020
Charles Bancroft, Non Executive Director, bought 1,733 shares in the company on ......
